MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Study ID
- NCT07619391
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Electronic Health Record Review — OTHERAncillary studies
- Smartphone Application-based Intervention — BEHAVIORALReceive access to MyCap application
- Survey Administration — OTHERAncillary studies
Study Details
This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant time coordinating appointments among different doctors. This time commitment is referred to as time toxicity, defined as the time spent undergoing cancer-related medical care, such as emergency visits, ambulatory care, lab and infusion visits, hospitalizations, and the commuting and waiting times associated with each. At present, time toxicity is still understudied within the medical literature, with no gold standard established for the method of measurement. The MyCap mobile app may be a feasible way to track the time burden from treatment for patients with pancreatic cancer.
Key Dates
- Start date
- Mar 10, 2026
- Status verified
- May 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Health Services Research (MyCap app)Patients download the MyCap app onto their phone and fill out a daily time log in the app for 8 weeks.
Primary Outcome Measure
Retention rate (feasibility) [ Time Frame: Up to 8 weeks ]
Central Contacts
- The Ohio State University Comprehensive Cancer Center800-293-5066
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Pamela W. Lu, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Columbus, OH
Related Studies
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruiting · Guardant Health, Inc. · Birmingham, Alabama
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Birmingham, Alabama
- A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic AdenocarcinomaPHASE2 · Recruiting · Ashish Manne · Columbus, Ohio
- Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACTPHASE1/PHASE2 · Recruiting · Case Comprehensive Cancer Center · Cleveland, Ohio